Clinical Trial Update: Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects [Phase 4]

View source ↗

Summary

This Phase 4 trial evaluated switching HIV patients from an NNRTI or protease inhibitor to maraviroc; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Maraviroc (maraviroc)

Snippet

Sponsor: Germans Trias i Pujol Hospital | Conditions: HIV, HIV Infections | Phase 4 | Status: COMPLETED